Acrux Ltd Investor Presentation and Full Year Results
Filed with ASX · · 16 pages · English
In the deck
Earlier from Acrux
- Appendix 4E & Full Year Statutory Accounts
- Jublia Patent Litigation Settlement
- Appendix 4D and Half-Year Financial Report to 31 Dec 2018
- Acrux Receives $2.057m R&D Tax Incentive Rebate
- Acrux has second generic dossier accepted for review by FDA
Later from Acrux
- Receipt of first R&D Tax Incentive Rebate
- Appendix 4D and Half Year Financial Report
- Acrux Signs Licensing Agreement With TruPharma
- Acrux Signs Co-Development Agreement With Amring
- Acrux Signs Licensing Agreement with Harris Pharmaceutical
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux